ESMO Breast 2020 | Targeting Low HER2 expression with antibody-drug conjugates
Giuseppe Curigliano
Giuseppe Curigliano, MD, PhD, University of Milano, Milan, Italy, discusses low HER2 expression metastatic breast cancer and its treatment with antibody-drug conjugates. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
Related videos
17:31 Prioritising patients for breast cancer surgery during COVID-19: a surgeon's perspective
Peter Barry
7:37 Prioritising patients for breast cancer surgery during COVID-19: new treatment algorithm
Mitch Dowsett
5:01 CDK4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
Cynthia X. Ma
2:24 DS-8201 + pembro in patients HER2+ breast and NSCLC
Sanjay Popat
2:20 Management of patients with breast cancer during COVID-19
Erin F. Cobain
